Canadian Guideline That Arose from Fibromyalgia Study Urges Medical Cannabis Caution

Canadian Guideline That Arose from Fibromyalgia Study Urges Medical Cannabis Caution
A study weighing the risks and benefits of cannabis-based therapies for fibromyalgia has led to University of Alberta researchers developing a guideline to help primary care doctors decide whether to recommend such treatments to their patients. The team that did the fibromyalgia review concluded that the risk of cannabinoids might outweight the benefits that patients with the disease would receive. At the moment, the guideline is a proposal. Its creators are seeking feedback on it before coming up with a final version. They published the "Simplified Guideline for Prescribing Medical Cannabinoids in Primary Care" in Canadian Family Physician. The guideline recommends that, in general, doctors limit their patients' medical cannabinoid use. But it does suggest that physicians consider the treatment for certain conditions when standard therapies fail. These include lingering nerve pain, chemotherapy-induced nausea and vomiting, and spasticity from multiple sclerosis or a spinal cord injury. Another use would be to address lingering pain in palliative care, or treatments that relieve symptoms rather than improve a disease. "While enthusiasm for medical marijuana is very strong among some people, good-quality research has not caught up," Mike Allan, who led the guideline creation process, said in a press release. The four uses of medical cannabis that the group reviewed before writing the guideline were relieving pain, nausea and vomiting, spasticity, and treatment side effects. The pain
Subscribe or to access all post and page content.